Immunohistochemical staining of Cytokeratin 19  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Cytokeratin 19 [A53-B/A2.26] Antibody (cGMP).

$ 128.00$ 588.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD117
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG2a, kappa

Product NumberDescriptionPrice
QIVD117-0.1ml Size: 0.1 ml, Format: Concentrate $ 128.00
QIVD117-0.5ml Size: 0.5 ml, Format: Concentrate $ 228.00
QIVD117-1ml Size: 1 ml, Format: Concentrate $ 378.00
QIVD117-6ml Size: 6 ml, Format: Predilute $ 228.00
QIVD117-25ml Size: 25 ml, Format: Predilute $ 588.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD117-0.1ml
Cytokeratin 19 General Information
Alternate Names
Molecular Weight
44.1 kDa
Chromosomal Location
q21.2 [chr: 17] [chr_start: 41523617] [chr_end: 41528308] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolKRT19
Entrez Gene ID3880
RefSeq Protein Accession(s)NP_002267
RefSeq mRNA Accession(s); NM_002276
RefSeq Genomic Accession(s)NC_000017; NG_012285
UniProt ID(s)P08727
PharmGKB ID(s)PA30225
KEGG Gene ID(s)hsa:3880
General Description of Cytokeratin 19 .
This antibody is specific to a 40 kDa protein, cytokeratin 19. Its epitope maps between amino acids 312-335. This antibody reacts with MCF-7 cells, which are known to contain cytokeratin 19.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Cytokeratin 19 Antibody Clone: A53-B/A2.26
Host and Isotype: Mouse IgG2a, kappa
Recommended Positive Control Sample: Skin, Tonsil
Cellular Localization of Antibody A53-B/A2.26 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with human breast cancer MCF-7 cells.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Cytokeratin 19 Information for Pathologists

Summary:

Molecular weight is 40 kDa (smallest cytokeratin). Often coexpressed with CK7. Present in both simple and complex epithelium. Involved in the organization of myofibers; links contractile apparatus to dystrophin at costameres of striated muscle (also CK8, Mol Biol Cell 2005;16:4280). Polymorphisms of CK19 pseudogene are associated with primary biliary cirrhosis (Hepatol Res 2003;25:281).

Common Uses By Pathologists:

Bladder: possible urine screening test for bladder carcinoma (J Egypt Natl Canc Inst 2006;18:82). Bone / soft tissue: distinguish chordoma (CK19+) from parachordoma (CK19-, Ann Diagn Pathol 1997;1:3). Breast: presence of CK19+ peripheral blood tumor cells or CK19+ fragments is a poor prognostic factor for breast cancer (predicts CNS relapse, Breast Cancer Res 2006;8:R36). Liver: distinguish hepatocellular carcinoma (CK19-) from either hepatoid adenocarcinoma metastatic to liver (CK19+, Am J Surg Pathol 2003;27:1302) or cholangiocarcinoma (CK19+, J Gastrointestin Liver Dis 2006;15:9, Am J Clin Pathol 2006;125:519). Liver: poor prognostic factor in hepatocellular carcinoma (Histopathology 2006;49:138, Cancer Sci 2003;94:851).

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Cytokeratin 19 [A53-B/A2.26] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Cytokeratin 19 [A53-B/A2.26] Antibody (cGMP).